Cargando…

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

BACKGROUND/AIM: Inflammatory bowel disease (IBD) is a chronic disorder affecting patients' quality of life and increasing their disability. The aim of our study was to evaluate clinical and pharmacological factors associated with impaired quality of life and disability in a large cohort of IBD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Carla, Savarino, Edoardo, Inferrera, Marco, Lorenzon, Greta, Rigo, Alessandra, Ghisa, Matteo, Facchin, Sonia, D'Incà, Renata, Zingone, Fabiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721452/ https://www.ncbi.nlm.nih.gov/pubmed/31531015 http://dx.doi.org/10.1155/2019/5354320

Ejemplares similares

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations
por: Ghisa, Matteo, et al.
Publicado: (2020)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
por: Barberio, Brigida, et al.
Publicado: (2020)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet
por: Marsilio, Ilaria, et al.
Publicado: (2020)

Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box
por: Barberio, Brigida, et al.
Publicado: (2019)

Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak
por: Savarino, Edoardo, et al.
Publicado: (2020)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
por: Facchin, Sonia, et al.
Publicado: (2020)

A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
por: Marsilio, Ilaria, et al.
Publicado: (2020)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
por: Marinelli, C., et al.
Publicado: (2020)

AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Marsilio, I., et al.
Publicado: (2021)

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak
por: Savarino, Edoardo Vincenzo, et al.
Publicado: (2020)

Biomarkers in IBD: What to Utilize for the Diagnosis?
por: D’Incà, Renata, et al.
Publicado: (2023)

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre
por: Zingone, Fabiana, et al.
Publicado: (2020)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis and GERD: links and risks
por: Ghisa, Matteo, et al.
Publicado: (2019)

Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa
por: Fassan, Matteo, et al.
Publicado: (2017)

Risk of COVID-19 in celiac disease patients
por: Zingone, Fabiana, et al.
Publicado: (2020)

Assessment of Nutritional Status by Bioelectrical Impedance in Adult Patients with Celiac Disease: A Prospective Single-Center Study
por: Maniero, Daria, et al.
Publicado: (2023)

The Lyon Consensus: Does It Differ From the Previous Ones?
por: Ghisa, Matteo, et al.
Publicado: (2020)

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study
por: Zingone, Fabiana, et al.
Publicado: (2020)

Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn’s disease and control subjects with no inflammatory bowel disease
por: Merigo, Flavia, et al.
Publicado: (2020)

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
por: Marabotto, Elisa, et al.
Publicado: (2020)

Glucose transporter expression in the human colon
por: Merigo, Flavia, et al.
Publicado: (2018)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis
por: Kotsafti, Andromachi, et al.
Publicado: (2019)

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
por: Zingone, Fabiana, et al.
Publicado: (2020)

Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach
por: Visaggi, Pierfrancesco, et al.
Publicado: (2021)

Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature
por: Ghisa, Matteo, et al.
Publicado: (2022)

Validation of the Padova Prognostic Score for Colitis in Predicting Long-Term Outcome After Restorative Proctocolectomy
por: Angriman, Imerio, et al.
Publicado: (2022)

In Silico Evaluation of Putative S100B Interacting Proteins in Healthy and IBD Gut Microbiota
por: Orsini, Massimiliano, et al.
Publicado: (2020)

Factors Predicting the Adherence to the Therapy of Italian IBD Patients
por: Bucci, Cristina, et al.
Publicado: (2017)

The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
por: Barberio, Brigida, et al.
Publicado: (2021)

No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy
por: Zingone, Fabiana, et al.
Publicado: (2020)

Non-Invasive and Minimally Invasive Biomarkers for the Management of Eosinophilic Esophagitis beyond Peak Eosinophil Counts: Filling the Gap in Clinical Practice
por: Visaggi, Pierfrancesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m8sf7vtooe1opm0q8dm0pk4qc6